Research Topics
| Sarah S DonaldsonSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSGS S Donaldson
Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 5302, USA
Int J Radiat Oncol Biol Phys 51:718-28. 2001..To evaluate the outcome and toxicity of hyperfractionated radiotherapy (HFRT) vs. conventionally fractionated radiotherapy (CFRT) in children with Group III rhabdomyosarcoma (RMS)...- Advances toward an understanding of brainstem gliomasSarah S Donaldson
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
J Clin Oncol 24:1266-72. 2006..Although we briefly discuss the nondiffuse tumors, we focus specifically on those diffuse brainstem tumors that regrettably still carry a bleak prognosis... - Subspecialty training and certification for radiation oncologySarah S Donaldson
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305 5302, USA
J Am Coll Radiol 1:488-92. 2004..As a result, the authors believe that subspecialty training and certification in radiation oncology is not a near-term possibility... - Ewing sarcoma: radiation dose and target volumeSarah S Donaldson
Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5847, USA
Pediatr Blood Cancer 42:471-6. 2004..However, the preferred assessment following radiation therapy is local control... - A discourse: the 2002 Wataru W. Sutow lecture. Hodgkin disease in children--perspectives and progressSarah S Donaldson
Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5302, USA
Med Pediatr Oncol 40:73-81. 2003.... - Pediatric Hodgkin's disease--up, up, and beyondSarah S Donaldson
Department of Radiation Oncology, Stanford University Medical Center, 300 Pasteur Drive, Rm A083, Stanford, CA 94305 5302, USA
Int J Radiat Oncol Biol Phys 54:1-8. 2002..The universal goal of cure without late effects is realistic for almost all children with Hodgkin's disease today... - VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trialSarah S Donaldson
Stanford University Medical Center, Stanford, CA, USA
J Clin Oncol 20:3081-7. 2002..To evaluate outcome and assess toxicity of children and adolescents with early-stage, favorable Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and low-dose, involved-field radiation... 
Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology GroupA Yuriko Minn
Stanford University Medical Center, Stanford, CA, USA
J Clin Oncol 28:4228-32. 2010..The goal of this study was to determine the frequency and clinical features of early treatment failure during induction chemotherapy before protocol radiation therapy for children with intermediate-risk rhabdomyosarcoma (RMS)...- Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's diseaseSarah S Donaldson
Stanford University Medical Center, Stanford, CA, USA
J Clin Oncol 25:332-7. 2007.... - Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology GroupTrang H La
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
Int J Radiat Oncol Biol Phys 80:1151-7. 2011..To evaluate the incidence and prognostic factors for regional failure, with attention to the in-transit pathways of spread, in children with nonmetastatic rhabdomyosarcoma of the extremity... - Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma StudyMoody D Wharam
Children s Oncology Group, Arvadia, CA, USA
J Clin Oncol 22:1902-8. 2004.... - Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology GroupTorunn I Yock
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 24:3838-43. 2006..We investigated the relationship between the type of local control modality, surgery, radiation (RT) or both (S + RT), and subsequent risk for local failure (LF) in patients with nonmetastatic pelvic Ewing sarcoma treated on INT-0091... - Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology GroupLeo Mascarenhas
Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
J Clin Oncol 28:4658-63. 2010..To compare response rates for two schedules of irinotecan with vincristine in patients with rhabdomyosarcoma at first relapse or disease progression... - Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology GroupChi Lin
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA
Int J Radiat Oncol Biol Phys 82:1764-70. 2012.... 
Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology GroupLynn Million
Department of Radiation Oncology, University of Utah Health Sciences and Huntsman Cancer Institute, Salt Lake City, UT, USA
Int J Radiat Oncol Biol Phys 80:333-8. 2011..We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control...- Prognostic factors for children with Hodgkin's disease treated with combined-modality therapyRon S Smith
Department of Radiation Oncology, Stanford University School of Medicine, CA, USA
J Clin Oncol 21:2026-33. 2003..Evaluation of pretreatment factors to identify children at high risk for relapse after combined-modality therapy for Hodgkin's disease... - High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indicesYeeYie E Lieskovsky
Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305-5847, USA
J Clin Oncol 22:4532-40. 2004..Further investigation is now required to determine the optimal timing of AHSCT, as well as to develop alternative regimens for those patients with factors prognostic for poor outcome after AHSCT... - Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology GroupTrang H La
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
Int J Radiat Oncol Biol Phys 80:206-12. 2011..To evaluate the outcome of children with rhabdomyosarcoma (RMS) of the hand or foot treated with surgery and/or local radiotherapy (RT)... - Controversies in radiotherapy for pediatric Hodgkin's lymphomaEllen A Wiegner
Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Expert Rev Anticancer Ther 11:1357-66. 2011..Response-adapted therapy is emerging as a promising strategy to attenuate therapy and thereby reduce toxicity in children with an excellent prognosis and intensify therapy in those children at higher risk of progression or relapse... - Profile of daily life in children with brain tumors: an assessment of health-related quality of lifeSundeep R Bhat
Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA
J Clin Oncol 23:5493-500. 2005..Children receiving XRT fare worse overall; chemotherapy added to XRT does not seem to worsen HRQOL. Assessment of HRQOL should be included as an outcome in future clinical trials... - Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IVJeff M Michalski
Department of Radiation Oncology, Washington University School of Medicine, Box 8224, 4921 Parkview Place, Lower Level, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 59:1027-38. 2004.... - Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapyChristopher C Dvorak
Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, Stanford University School of Medicine, Palo Alto, California 94304, USA
Pediatr Blood Cancer 48:582-5. 2007..These cases demonstrate that there is a role for ATRA plus differentiating chemotherapy other than arsenic trioxide in the treatment of relapsed APML... - Treatment of pediatric hodgkin lymphomaMichael R Olson
Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305 5847, USA
Curr Treat Options Oncol 9:81-94. 2008..The majority of children failing combined-modality treatment undergo high-dose chemotherapy followed by autologous hematopoietic stem cell rescue, oftentimes with consolidative radiotherapy... - Radiation therapy for intracranial germ cell tumorsDaphne A Haas-Kogan
Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
Int J Radiat Oncol Biol Phys 56:511-8. 2003.... - Resectable pediatric nonrhabdomyosarcoma soft tissue sarcoma: which patients benefit from adjuvant radiation therapy and how much?Lynn Million
Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
ISRN Oncol 2012:341408. 2012..This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence rates in relationship to the use of radiation therapy... - Primary radiotherapy for localized orbital MALT lymphomaQuynh Thu Le
Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
Int J Radiat Oncol Biol Phys 52:657-63. 2002..To define the natural history, prognosis, and radiocurability of localized orbital extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)... - Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997Richard Beverly Raney
Department of Clinical Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Med Pediatr Oncol 38:22-32. 2002..We reviewed 611 patients with parameningeal sarcoma entered on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-II through IV (1978-1997), to delineate treatment results and evaluate prognostic factors... - Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiationAlison M Friedmann
Pediatric Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 20:3088-94. 2002.... - Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of boneHolcombe E Grier
Department of Pediatric Hematology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
N Engl J Med 348:694-701. 2003..We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease... - Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group studyJames S Miser
City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
J Clin Oncol 22:2873-6. 2004.... - Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology GroupBeverly Raney
Children s Cancer Hospital, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Pediatr Blood Cancer 51:17-22. 2008..Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV... - Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology GroupAlberto S Pappo
Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
J Clin Oncol 25:362-9. 2007.... - Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor StudyDaniel C Bowers
Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9063, USA
J Clin Oncol 23:6508-15. 2005..The objectives of this report are to examine the incidence of and risk factors for stroke among childhood Hodgkin's disease (HD) survivors... - Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology groupSheri L Spunt
St Jude Children s Research Hospital and University of Tennessee College of Medicine, Memphis, Tennessee 38105 2794, USA
Clin Cancer Res 10:6072-9. 2004..More than half of pediatric rhabdomyosarcoma cases have intermediate-risk features and suboptimal outcome (3-year failure-free survival estimates, 55 to 76%). Dose intensification of known active agents may improve outcome... - Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's diseaseMelissa M Hudson
Department of Hematology Oncology, Radiological Sciences and Biostatistics, St Jude Children s Research Hospital and the University of Tennessee College of Medicine, Memphis, TN 38105, USA
J Clin Oncol 22:4541-50. 2004.... - Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupLillian Sung
The Division of Hematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ont, M5G 1X8, Canada
Eur J Cancer 40:1878-85. 2004..Late events after successful treatment for rhabdomyosarcoma occur in 9%. Those with advanced disease and large primary tumours have the highest risk of late events... - Rhabdomyosarcoma: many similarities, a few philosophical differencesSarah S Donaldson
J Clin Oncol 23:2586-7. 2005 - Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IVJohn C Breneman
Children s Hospital Medical Center, Division of Radiation Oncology, Cincinnati, OH 45219 0757, USA
J Clin Oncol 21:78-84. 2003..To identify risk factors associated with outcomes in children with metastatic rhabdomyosarcoma (RMS) treated on the fourth Intergroup Rhabdomyosarcoma Study (IRS-IV)... - Genetic effects of radiotherapy for childhood cancer: gonadal dose reconstructionMarilyn Stovall
Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 60:542-52. 2004.... - Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IVAlberto S Pappo
Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
J Clin Oncol 21:638-45. 2003..The characteristics and clinical outcomes of children and adolescents with localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma (RMS) treated on national protocols from the Intergroup Rhabdomyosarcoma Group are reported... - Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiersCécile M Ronckers
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland
Radiat Res 166:618-28. 2006..In summary, we applied models derived from radiobiology to describe the radiation dose-response curve for thyroid cancer in an epidemiological study and found convincing evidence for a downturn in risk at high doses... - Understanding the risk of second malignant tumors in children with Hodgkin's diseaseSarah S Donaldson
Int J Radiat Oncol Biol Phys 72:4-5. 2008 - Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997R Beverly Raney
Department of Clinical Pediatrics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Pediatr Blood Cancer 42:618-25. 2004..We reviewed 56 IRS-IV patients with localized rhabdomyosarcoma [RMS] of the retroperitoneum/pelvis to assess outcome and prognostic factors, including the value of initially excising >or=50% of the tumor (debulking) before chemotherapy... - New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor StudyJoseph P Neglia
Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN, USA
J Natl Cancer Inst 98:1528-37. 2006..However, the details of the dose-response relationships, the expression of excess risk over time, and the modifying effects of other host and treatment factors have not been well defined... - Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology GroupJames S Miser
Division of Pediatrics, Department of Pediatric Hematology Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
Pediatr Blood Cancer 49:894-900. 2007..We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis... - Continuing medical education in radiology: a glimpse of the present and of what lies aheadLawrence P Davis
Department of Radiology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
J Am Coll Radiol 2:338-43. 2005..The ACR supports the radiology and radiation oncology community in their efforts at lifelong learning and is developing new and innovative educational programs and tools to accomplish this goal... - Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudyElizabeth C Bluhm
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7238, Rockville, MD 20892 7238, USA
Blood 111:4014-21. 2008..1), mediastinal NHL disease (RR = 5.2), and breast irradiation (RR = 4.3). Survivors of childhood NHL, particularly those treated with chest RT, are at continued increased risk of early mortality and solid tumor SMNs...